Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 301–400 of 1,013
Wang, L., Lin, X., Wang, J., Hu, Z., Ji, Y., Hou, S., Zhao, Y., Wu, X., & Chen, C. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201400015 · Cited by 159
Salcido, C. D., Larochelle, A., Taylor, B. J., Dunbar, C. E., & Varticovski, L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605668 · Cited by 153
“Second, expression of ABC transporters is associated with drug resistance that is characteristic of stem cells from normal and malignant tissues (Szakacs et al, 2006).”
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Williams, E. M., Little, R. F., Mowday, A. M., Rich, M. H., Chan-Hyams, J. V. E., Copp, J. N., Smaill, J. B., Patterson, A. V., & Ackerley, D. F. (2015) · Biochemical Journal · doi:10.1042/bj20150650 · Cited by 171
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
Arnst, K. E., Banerjee, S., Chen, H., Deng, S., Hwang, D., Li, W., & Miller, D. D. (2019) · Medicinal Research Reviews · doi:10.1002/med.21568 · Cited by 161
Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi‐Birjand, M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.28967 · Cited by 152
“More importantly, drug transporters mainly facilitate the efflux of hydrophobic compounds (Szakacs, Paterson, Ludwig, Booth ‐ Genthe, & Gottesman, 2006; Takeshita et al., 2009).”
BackgroundRecent advances for enhanced photodynamic therapy: from new mechanisms to innovative strategies
Wang, X., Peng, J., Meng, C., & Feng, F. (2024) · Chemical Science · doi:10.1039/d3sc07006a · Cited by 178
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 176
Yao, H.-J., Ju, R.-J., Wang, X., Zhang, Y., Li, R., Yu, Y., Zhang, L., & Lü, W.-L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.038 · Cited by 151
“binding cassette (ABC) transporter family (most notably P-glycoprotein, P-gp) is responsible for the MDR [9].”
BackgroundInfluentialEpithelial-mesenchymal transition and drug resistance in breast cancer (Review)
Huang, J., Li, H., & Ren, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3084 · Cited by 160
Yao, N., Wang, C., Hu, N., Li, Y., Liu, M., Lei, Y., Chen, M., Chen, L., Chen, C., Lan, P., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1470-z · Cited by 160
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., & Jiang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00487 · Cited by 159
“MDR may be due to different mechanisms, including (1) ATP-binding cassette (ABC) transporters that pump out chemotherapeutics (3), (2) the mutation of oncogenes that become resistant to former treatments (4, 5), (3) an evolving adaptation of cancer cells to the microenvironment (6, 7), (4) survived cancer stem cells (…”
BackgroundInfluentialATP‐binding cassette (ABC) transporters in cancer: A review of recent updates
Wang, J., Wu, Z., Yang, Y., Teng, Q., Li, Y., Lei, Z., Jani, K. A., Kaushal, N., & Chen, Z. (2021) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12434 · Cited by 143
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor
Riccioni, R., Dupuis, M. L., Bernabei, M., Petrucci, E., Pasquini, L., Mariani, G., Cianfriglia, M., & Testa, U. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.03.008 · Cited by 161
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
Lin, G., Mi, P., Chu, C., Zhang, J., & Liu, G. (2016) · Advanced Science · doi:10.1002/advs.201600134 · Cited by 149
Cancer stem cells and oncology therapeutics
Al-Hajj, M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a8d6 · Cited by 148
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Erkan, M., Kurtoğlu, M., & Kleeff, J. H. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1117386 · Cited by 165
“gradient reducing their intracellular concentration and thereby toxic activity.[67] Overall, there is strong evidence supporting the role of hypoxia and HIF-1 in”
BackgroundABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis
Helias, V., Saison, C., Ballif, B. A., Peyrard, T., Takahashi, J., Takahashi, H. K., Tanaka, M., Deybach, J., Puy, H., Gall, M. L., et al. (2012) · Nature Genetics · doi:10.1038/ng.1069 · Cited by 147
“Thus, ABCB6 could transport anticancer drugs as well as endogenous substrates, similar to ABCB1 and other multidrug ABC transporter”
BackgroundYadav, S. K., van Vlerken, L. E., Little, S. R., & Amiji, M. M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0790-y · Cited by 152
“Acquired MDR is thought to be the primary reason for the poor eYcacy of cancer chemotherapy, especially in ovarian and breast cancers, where up to 50–70% of the patients develop MDR [3, 4].”
BackgroundZhang, W., Wang, F., Wang, Y., Wang, J., Yu, Y., Guo, S., Chen, R., & Zhou, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.001 · Cited by 152
“MDR is a leading cause of cancer chemotherapy failure [5,6], mainly caused by cancer cell surface overexpressed efflux transporters which can effectively efflux out therapeutic drugs, preventing drug accumulation and compromising therapeutic efficacy [7-12].”
BackgroundAlbumin-based nanoparticles: a promising strategy to overcome cancer drug resistance
Hassanin, I. A., & Elzoghby, A. O. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.68 · Cited by 200
“Moreover, drug inactivation, drug efflux, reduced drug uptake, resistance to apoptosis, enhanced DNA repair mechanisms, and immunosuppression and immune evasion are cancer resistance mechanisms which may negatively influence anti-cancer drug treatment([6-8]).”
BackgroundCancer Cell Invasion: Treatment and Monitoring Opportunities in Nanomedicine
Veiseh, O., Kievit, F. M., Ellenbogen, R. G., & Zhang, M. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.010 · Cited by 158
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 161
Miyata, H., Takada, T., Toyoda, Y., Matsuo, H., Ichida, K., & Suzuki, H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00518 · Cited by 158
“Considering the diversity of substrate specificity in ABC transporters that is responsible for the multidrug efflux (Haimeur et al., 2004; Szakacs et al., 2006; Toyoda et al., 2008; Giacomini et al., 2010), the inhibitory effect of febuxostat on the other ABC transporters such as ABCB1 (known as…”
BackgroundMethodGautier, J., Allard-Vannier, É., Munnier, E., Soucé, M., & Chourpa, I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.018 · Cited by 161
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
“In the upcoming years, several other proteins of the ABC transporter family were identified that shared a common mechanism of conferring chemotherapy resistance by drug efflux (4).”
BackgroundMolecular Vehicles for Mitochondrial Chemical Biology and Drug Delivery
Jean, S. R., Tulumello, D. V., Wisnovsky, S., Lei, E. K., Pereira, M. P., & Kelley, S. O. (2014) · ACS Chemical Biology · doi:10.1021/cb400821p · Cited by 156
Dual-Stimuli Responsive Bismuth Nanoraspberries for Multimodal Imaging and Combined Cancer Therapy
Li, Z., Hu, Y., Miao, Z., Xu, H., Li, C., Zhao, Y., Li, Z., Chang, M., Ma, Z., Sun, Y., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02639 · Cited by 143
Shukla, S., Zaher, H., Hartz, A., Bauer, B., Ware, J. A., & Ambudkar, S. V. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9735-8 · Cited by 144
“Some of the ABC transporters play a crucial role in the development of multidrug resistance (MDR), as patients that are undergoing chemotherapy can eventually develop resistance not only to the anticancer drug they are taking but also to several other types of drugs (9).”
InfluentialPharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein SubstrateR‐[11C]verapamil
Langer, O., Bauer, M., Hammers, A., Karch, R., Pataraia, E., Koepp, M. J., Abrahim, A., Luurtsema, G., Brunner, M., Sunder‐Plaßmann, R., et al. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01116.x · Cited by 157
“Several new third-generation P-gp inhibitors, such as tariquidar (XR-9576), are currently in clinical development (Szakacs et al., 2006).”
BackgroundThe Expression Profile of Atp-Binding Cassette Transporter Genes in Breast Carcinoma
Hlaváč, V., Brynychová, V., Václavíková, R., Ehrlichová, M., Vrána, D., Pecha, V., Koževnikovová, R., Trnková, M., Gatěk, J., Kopperová, D., et al. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.26 · Cited by 141
Wei, X., Wang, Y., Xiong, X., Guo, X., Zhang, L., Zhang, X., & Zhou, S. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603336 · Cited by 151
A Versatile Carbon Monoxide Nanogenerator for Enhanced Tumor Therapy and Anti-Inflammation
Wang, S., Zhang, C., Chen, Z., Ye, J., Peng, S., Rong, L., Liu, C., & Zhang, X. (2019) · ACS Nano · doi:10.1021/acsnano.9b00345 · Cited by 145
Ruttala, H. B., & Ko, Y. T. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.02.040 · Cited by 141
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Preti, D., Tabrizi, M. A., Brancale, A., Fu, X., Li, J., Zhang, S., Hamel, E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2013979 · Cited by 142
Dong, Z., Zhong, Z., Yang, L., Wang, S., & Gong, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.034 · Cited by 145
“However, the continuous infusion or multiple administration of DDP often results in the development of drug resistance, which leads to treatment failure, as demonstrated by tumor growth or tumor relapse [2,3].”
BackgroundABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Lin, F., de Gooijer, M. C., Roig, E. M., Buil, L. C. M., Christner, S. M., Beumer, J. H., Würdinger, T., Beijnen, J. H., & van Tellingen, O. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0084 · Cited by 143
External-stimuli responsive systems for cancer theranostic
Yao, J., Feng, J., & Chen, J. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.06.001 · Cited by 163
Ma, X., Zhou, J., Zhang, C.-X., Li, X., Li, N., Ju, R.-J., Shi, J., Sun, M., Zhao, W., Mu, L.-M., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.066 · Cited by 140
Computational models for predicting substrates or inhibitors of P-glycoprotein
Chen, L., Li, Y., Yu, H., Zhang, L., & Hou, T. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.003 · Cited by 155
Chemotherapy resistance mechanisms in advanced skin cancer
Kalal, B. S., Upadhya, D., & Pai, V. R. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.326 · Cited by 168
Guo, Y., Jiang, K., Shen, Z., Zheng, G., Fan, L., Zhao, R., & Shao, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14755 · Cited by 143
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 150
“Diverse genetic and epigenetic alterations play a fundamental role in tumorigenesis, progression, and development of drug resistance during the treatment course [4, 5].”
BackgroundClock and ATF4 transcription system regulates drug resistance in human cancer cell lines
IGARASHI, T., Izumi, H., Uchiumi, T., Nishio, K., Arao, T., Tanabe, M., Uramoto, H., Sugio, K., Yasumoto, K., Sasaguri, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210289 · Cited by 158
“Oncogene P-glycoprotein.”
BackgroundInfluentialHuang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 144
“(23) PDT, an FDA-approved regimen with non-overlapping toxicities, provides a unique opportunity for inhibition of irinotecan efflux transporters, while avoiding those toxicity-related pitfalls.”
BackgroundLiu, J., Zhang, L., Lei, J., Shen, H., & Ju, H. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14446 · Cited by 139
Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy
Li, M., Sun, J., Zhang, W., Zhao, Y., Zhang, S., & Zhang, S. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117103 · Cited by 150
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 150
Huang, M., Zhang, D., Wu, J. Y., Xing, K., Yeo, E., Li, C., Zhang, L., Holland, E., Yao, L., Qin, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay7522 · Cited by 139
Multidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
“These in vivo selected tumors are refractory to growth inhibition caused by a wide range of different chemotherapeutics, even drugs to which the patient was not previously exposed (Szakacs et al., 2006).”
BackgroundInfluentialvan Waterschoot, R. A. B., & Schinkel, A. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002584 · Cited by 151
“Recent studies with CYP3A knockout and transgenic mice have yielded a number of key insights that are important to consider during drug discovery and development.”
BackgroundThe therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Merien, F., Lu, J., Liu, D.-X., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 135
“These compounds inhibited hepatic and intestinal CYP enzymes, decreasing the metabolism and clearance of the substrate drugs, thereby causing systemic toxicity [74,75,94].”
BackgroundMeng, L., Zhang, W., Li, D., Li, Y., Hu, X., Wang, L., & Li, G. (2015) · Chemical Communications · doi:10.1039/c5cc05785j · Cited by 142
Perche, F., Patel, N. R., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.003 · Cited by 135
“Cancer therapy remains a challenge due to cancer resistance mechanism and systemic toxicity [6-8].”
BackgroundReversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles
Yu, P., Yu, H., Guo, C., Cui, Z., Chen, X., Yin, Q., Zhang, P., Yang, X., Cui, H., & Li, Y. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.12.001 · Cited by 137
Design of a Tumor-Homing Cell-Penetrating Peptide
Myrberg, H., Zhang, L., Mäe, M., & Langel, Ü. (2008) · Bioconjugate Chemistry · doi:10.1021/bc0701139 · Cited by 137
Gooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 152
“Additional means undertaken by breast carcinoma cells to circumvent the cytotoxic activities of chemotherapies include their ability to (i) upregulate the expression of antiapoptotic proteins; (ii) sequester drugswithin intracellular compartments, thereby preventing access to theirmolecular targets; (iii) induce the e…”
BackgroundZeng, X., Morgenstern, R., & Nyström, A. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.042 · Cited by 136
“Drug resistance is correlated with a variety of biochemical changes, including increased efflux of the cytotoxic drugs due to overexpression of the ATP-binding cassette transporters, DNA repair activation, and altered levels of apoptosis [5,6].”
BackgroundSong, W., Tang, Z., Zhang, D., Zhang, Y., Yu, H., Li, M., Lv, S., Sun, H. Y., Deng, M., & Chen, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.018 · Cited by 135
“Another problem is the treatment with a single drug often encounters multi-drug resistance, and this greatly discounts the tumor inhibition effect [17,18].”
BackgroundDöring, B., & Petzinger, E. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.882353 · Cited by 135
“List of human ABC carriers maintaining the efflux of drugs (for a review, see Borst & Oude Elferink, 2002; Szakács et al., 2006; Giacomini et al., 2010).”
BackgroundLi, S., Zhao, Q., Wang, B., Yuan, S., Wang, X., & Li, K. (2018) · Phytotherapy Research · doi:10.1002/ptr.6081 · Cited by 143
Solomon, V. R., Hu, C., & Lee, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.001 · Cited by 135
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter
Telbisz, Á., Müller, M., Özvegy‐Laczka, C., Homolya, L., Szente, L., Váradi, A., & Sarkadi, B. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.06.026 · Cited by 139
“The significant substrate-stimulation of the humanMDR1-ATPase activity in Sf9 membranes has also been extensively documented [4,39].”
BackgroundInfluentialBarui, S., Saha, S., Mondal, G., Haseena, S., & Chaudhuri, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.074 · Cited by 140
“Small synthetic molecules as well as antibodies targeted against MDR proteins have been used in the past, but they have failed in clinical trials mostly due to their toxicity and low serum stability [29].”
BackgroundSun, L., Wang, D., Chen, Y., Wang, L., Huang, P., Li, Y., Liu, Z., Yao, H., & Shi, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.028 · Cited by 136
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Zhang, M., Liu, E., Cui, Y., & Huang, Y. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0054 · Cited by 145
Yu, G., Zhu, B., Shao, L., Zhou, J., Saha, M. L., Shi, B., Zhang, Z., Hong, T., Li, S., Chen, X. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902029116 · Cited by 136
Human ABCB6 Localizes to Both the Outer Mitochondrial Membrane and the Plasma Membrane
Paterson, J. K., Shukla, S., Black, C. M., Tachiwada, T., Garfield, S., Wincovitch, S., Ernst, D. N., Agadir, A., Li, X., Ambudkar, S. V., et al. (2007) · Biochemistry · doi:10.1021/bi700015m · Cited by 134
Self-citationChemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling
Frederiksen, L. J., Sullivan, R., Maxwell, L. R., Macdonald-Goodfellow, S. K., Adams, M. A., Bennett, B. M., Siemens, D. R., & Graham, C. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1807 · Cited by 133
van der Heijden, J. W., Dijkmans, B. A. C., Scheper, R. J., & Jansen, G. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0380 · Cited by 134
Secondary mutations of BRCA1/2 and drug resistance
Dhillon, K. K., Swisher, E. M., & Taniguchi, T. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01840.x · Cited by 149
Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug
Cardaci, S., Desideri, E., & Ciriolo, M. R. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9422-7 · Cited by 140
Bioengineering 3D environments for cancer models
Alemany‐Ribes, M., & Semino, C. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.004 · Cited by 151
“Furthermore, 3D models can also help in gaining a deeper understanding of the mechanisms that confer multidrug resistance (expression of efflux transporters, deregulation of cellular metabolism involving DNA repair, apoptosis or cell cycle signaling and decrease drug uptake) and, as a consequence, develop drugs capabl…”
BackgroundImportance of Drug Pharmacokinetics at the Site of Action
Rizk, M., Zou, L., Savic, R., & Dooley, K. (2017) · Clinical and Translational Science · doi:10.1111/cts.12448 · Cited by 131
Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review
Yang, Z., Huang, S., Zhou, D.-D., Xiong, R.-G., Zhao, C., Fang, A., Zhang, Y., Li, H., & Zhu, H. (2022) · Antioxidants · doi:10.3390/antiox11081481 · Cited by 322
“The biggest obstacle in targeting cancer therapy is the inevitable emergence of drug resistance in the early or late stages of drug treatment, which is a major clinical problem [128].”
BackgroundMei, L., Zhang, Y., Zheng, Y., Tian, G., Song, C. X., Yang, D., Chen, H., Sun, H., Tian, Y., Liu, K., et al. (2009) · Nanoscale Research Letters · doi:10.1007/s11671-009-9431-6 · Cited by 135
“Furthermore, recent studies indicated that Pluronic F68 is a potent in vitro inhibitor of both P-gp and CYP3A4 [16].”
BackgroundThe interplay between DNA repair and autophagy in cancer therapy
Zhang, D., Tang, B., Xie, X., Xiao, Y., Yang, S., & Zhang, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046022 · Cited by 138
Multidrug Resistance in Cancer
Baguley, B. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_1 · Cited by 160
“The first is to co-administer a drug that inhibits the action of the transporter (42), while the second is to design or utilise anticancer drugs whose activity is not significantly altered by the presence of transporters (43).”
BackgroundNanotechnology platforms for cancer immunotherapy
Yang, Z., Ma, Y., Hai, Z., Yuan, Y., & Kim, B. Y. S. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1590 · Cited by 142
Abd-Ellatef, G. E. F., Gazzano, E., Chirio, D., Hamed, A. R., Belisario, D. C., Zuddas, C., Peira, E., Rolando, B., Kopecka, J., Marie, M. A. S., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020096 · Cited by 136
“The latest frontier in Pgp inhibition is the co-administration of antineoplastic agents with pumps inhibitors [10,11].”
BackgroundNew insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Zhang, C., Wei-Qi, J., & Jin, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188382 · Cited by 138
Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells
Mei, M., Ren, Y., Zhou, X., Yuan, X.-B., Han, L., Wang, G.-X., Jia, Z., Pu, P.-Y., Kang, C.-S., & Yao, Z. (2010) · Technology in Cancer Research & Treatment · doi:10.1177/153303461000900109 · Cited by 132
Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors
Fabbro, D., Cowan-Jacob, S. W., Möbitz, H., & Martiny-Baron, G. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_1 · Cited by 127
Lorz, A., Lorenzi, T., Clairambault, J., Escargueil, A. E., & Perthame, B. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-0046-4 · Cited by 147
Singh, S. P., Mishra, A., Shyanti, R. K., Singh, R. P., & Acharya, A. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02255-z · Cited by 131
Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals
Nabekura, T., Yamaki, T., Ueno, K., & Kitagawa, S. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0676-4 · Cited by 128
“However, due to the side eVects or ineVectiveness of these compounds, a successful outcome has not been achieved [17].”
InfluentialThe ABCG2 resistance network of glioblastoma.
Bleau, A., Huse, J. T., & Holland, E. C. (2009) · PubMed · Cited by 138
Therapeutic strategies to improve drug delivery across the blood-brain barrier
Azad, T. D., Pan, J., Connolly, I. D., Remington, A., Wilson, C. M., & Grant, G. A. (2015) · Neurosurgical Focus · doi:10.3171/2014.12.focus14758 · Cited by 125
Punfa, W., Yodkeeree, S., Pitchakarn, P., Ampasavate, C., & Limtrakul, P. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.34 · Cited by 131
Gut bitter taste receptor signalling induces ABCB1 through a mechanism involving CCK
Jeon, T.-I., Seo, Y.-K., & Osborne, T. F. (2011) · Biochemical Journal · doi:10.1042/bj20110009 · Cited by 127
On the Origin of Large Flexibility of P-glycoprotein in the Inward-facing State
Wen, P.-C., 溫, 博., Verhalen, B., Wilkens, S., Mchaourab, H. S., & Tajkhorshid, E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.450114 · Cited by 129
“Among various ABC transporters contributing tomultidrug resistance, P-glycoprotein (Pgp,(3) also known as MDR1 or ABCB1) is most prominent, as it confers the strongest formof resistance against a wide spectrum of chemotherapeutic drugs in many tissue types (1).”
BackgroundLi, Y., Xu, X., Zhang, X., Li, Y., Zhang, Z., & Gu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06161 · Cited by 127
Li, R., & Xie, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.020 · Cited by 133
Salinomycin: A new paradigm in cancer therapy
Dewangan, J., Srivastava, S., & Rath, S. K. (2017) · Tumor Biology · doi:10.1177/1010428317695035 · Cited by 138
ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?
Steinbach, D., & Legrand, O. (2007) · Leukemia · doi:10.1038/sj.leu.2404692 · Cited by 142
Transport proteins of the ABC family and multidrug resistance of tumor cells
Stavrovskaya, A. A., & Stromskaya, T. P. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050118 · Cited by 146
Song, W., Tang, Z., Li, M., Lv, S., Sun, H., Deng, M., Liu, H., & Chen, X. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.11.026 · Cited by 126
“In small-molecule-based chemotherapy, the use of a single agent often fails to achieve complete cancer remission due to the rapid development of drug resistance in tumor cells [1].”
BackgroundBreast cancer, side population cells and ABCG2 expression
Britton, K. M., Eyre, R., Harvey, I. J., Stemke‐Hale, K., Browell, D., Lennard, T. W. J., & Meeson, A. P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.041 · Cited by 126
“, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, ABCC11, ABCC12 and ABCG2 which are capable of effluxing these agents [38] and may be responsible for the SP phenotype.”
BackgroundCharge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine
Zhang, M., Chen, X., Li, C., & Shen, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.024 · Cited by 126
Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Zhu, Y., Liu, C., Nadiminty, N., Lou, W., Tummala, R., Evans, C. P., & Gao, A. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0208 · Cited by 124
Chen, D., Tang, Q., Zou, J., Yang, X., Huang, W., Zhang, Q., Shao, J., & Dong, X. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701272 · Cited by 125
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.